Jefferies Cuts Estimate & Raises Price Target on BioMarin Pharmaceutical (BMRN), Maintains Buy Rating
Tweet Send to a Friend
Jefferies is maintaining their Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) even as the company reported their 4Q EPS ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
